{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T18:22:35Z","timestamp":1778610155276,"version":"3.51.4"},"reference-count":176,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1517\/13543776.2010.505604","type":"journal-article","created":{"date-parts":[[2010,7,21]],"date-time":"2010-07-21T01:47:23Z","timestamp":1279676843000},"page":"1123-1145","source":"Crossref","is-referenced-by-count":72,"title":["17\u03b2-Hydroxysteroid dehydrogenase inhibitors: a patent review"],"prefix":"10.1517","volume":"20","author":[{"given":"Donald","family":"Poirier","sequence":"first","affiliation":[{"name":"Laval University, CHUQ (CHUL) - Research Center, Endocrinology and Genomic Unit, Laboratory of Medicinal Chemistry, 2705 Laurier Boulevard, Qu\u00e9bec (Qu\u00e9bec), G1V 4G2, Canada ; ;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2010,7,20]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1039\/b705948p"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1216276"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.11.10.1523"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1039\/a902202c"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/cc030118m"},{"key":"e_1_3_2_8_1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/978-94-011-3060-8_9","volume-title":"Hormones: from molecules to disease","author":"Milgrom E","year":"1990","unstructured":"Milgrom E. Steroid hormones. In: Baulieu EE, Kelly PA, editors, Hormones: from molecules to disease. Hermann, publishers in arts and science, Paris; 1990. p. 385-437"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2003-0030"},{"key":"e_1_3_2_10_1","first-page":"177","volume-title":"Progress in brain research (Chapter 10)","author":"Luu-The V","year":"2010","unstructured":"Luu-The V, Labrie F. The intracrine sex steroid biosynthesis pathways. In: Martini L, editor, Progress in brain research (Chapter 10). Volume 181. Elsevier; 2010. p. 177-92"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0303-7207(91)90116-A"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2001-0031"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.2325\/jbcs.13.129"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.20263"},{"key":"e_1_3_2_15_1","unstructured":"von Angerer E. The estrogen receptor as a target for rational drug design. In: Landes RG editor Molecular Biology Intelligence Unit Company Austin TX; 1995"},{"key":"e_1_3_2_16_1","first-page":"279","article-title":"Estrogen actions in the central nervous system","volume":"20","author":"McEwen BS","year":"1999","unstructured":"McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev 1999;20:279-307","journal-title":"Endocr Rev"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867003375371"},{"key":"e_1_3_2_18_1","doi-asserted-by":"crossref","unstructured":"Bagatell CJ Bremner WJ. Androgens in health and disease. Humana Press: Totowa NJ; 2003","DOI":"10.1385\/1592593887"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/10253890400019672"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1677\/JME-08-0093"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm020450x"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0b013e32832a3d79"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-52-3-287"},{"key":"e_1_3_2_24_1","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/1731189a0","article-title":"Enzymatic formation of 3 alpha-hydroxysteroids","volume":"173","author":"Talalay P","year":"1954","unstructured":"Talalay P, Marcus PI. Enzymatic formation of 3 alpha-hydroxysteroids. Nature 1954;173:1189-90","journal-title":"Nature"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)65834-X"},{"key":"e_1_3_2_26_1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1098\/rspb.1955.0038","article-title":"On the molecular specificity of steroid-enzyme combinations. The kinetics of hydroxy-steroid dehydrogenase","volume":"144","author":"Marcus PI","year":"1955","unstructured":"Marcus PI, Talalay P. On the molecular specificity of steroid-enzyme combinations. The kinetics of hydroxy-steroid dehydrogenase. Proc R Soc Lond B 1955;144:116-32","journal-title":"Proc R Soc Lond B"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)64708-8"},{"key":"e_1_3_2_28_1","first-page":"139","article-title":"Human placental 17beta-estradiol dehydrogenase: characterization and structural studies","volume":"30","author":"Engel LL","year":"1974","unstructured":"Engel LL, Groman EV. Human placental 17beta-estradiol dehydrogenase: characterization and structural studies. Recent Prog Horm Res 1974;30:139-69","journal-title":"Recent Prog Horm Res"},{"key":"e_1_3_2_29_1","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1021\/cg700709k","article-title":"Crystallogenesis of steroid-converting enzymes and their complexes: enzyme-ligand interaction studies and inhibitor design facilitated by complex structures","volume":"7","author":"Mazumdar M","year":"2007","unstructured":"Mazumdar M, Zhou M, Zhu DW, Crystallogenesis of steroid-converting enzymes and their complexes: enzyme-ligand interaction studies and inhibitor design facilitated by complex structures. Crystal Growth Des 2007;7:2206-12","journal-title":"Crystal Growth Des"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.3109\/14756369109080057"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2008.01.008"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2008.10.040"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2008.03682.x"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2005.12.007"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-128X(96)00174-2"},{"key":"e_1_3_2_36_1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00441-005-1105-9","article-title":"Localization of type 5 17beta-hydroxysteroid dehydrogenase mRNA in mouse tissues as studied by in situ hybridization","volume":"320","author":"Pelletier G","year":"2005","unstructured":"Pelletier G, Luu-The V, Li S, Labrie F. Localization of type 5 17beta-hydroxysteroid dehydrogenase mRNA in mouse tissues as studied by in situ hybridization. Cell Tissue Res 2005;320:393-8","journal-title":"Cell Tissue Res"},{"key":"e_1_3_2_37_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jsbmb.2004.10.018","article-title":"Localization of type 7 17beta-hydroxysteroid dehydrogenase in mouse tissues. In situ hybridization studies","volume":"93","author":"Pelletier G","year":"2005","unstructured":"Pelletier G, Luu-The V, Li S, Labrie F. Localization of type 7 17beta-hydroxysteroid dehydrogenase in mouse tissues. In situ hybridization studies. J Steroid Biochem Mol Biol 2005;93:49-57","journal-title":"J Steroid Biochem Mol Biol"},{"key":"e_1_3_2_38_1","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1369\/jhc.5A6692.2005","article-title":"Localization of type 8 17beta-hydroxysteroid dehydrogenase mRNA in mouse tissues as studied by in situ hybridization","volume":"53","author":"Pelletier G","year":"2005","unstructured":"Pelletier G, Luu-The V, Li S, Labrie F. Localization of type 8 17beta-hydroxysteroid dehydrogenase mRNA in mouse tissues as studied by in situ hybridization. J Histochem Cytochem 2005;53:1257-71","journal-title":"J Histochem Cytochem"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2006.01.010"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(95)00209-X"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3140839"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2008.08.026"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2006.06.015"},{"key":"e_1_3_2_44_1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0960-0760(96)81857-7","article-title":"Introduction to the workshop on the molecular and cell biology of hydroxysteroid dehydrogenases","volume":"55","author":"Adamski J","year":"1995","unstructured":"Adamski J, de Launoit Y. Introduction to the workshop on the molecular and cell biology of hydroxysteroid dehydrogenases. J Steroid Biochem Mol Biol 1995;55:445-6 (and publications in this special issue)","journal-title":"J Steroid Biochem Mol Biol"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0303-7207(00)00383-X"},{"key":"e_1_3_2_46_1","first-page":"1","article-title":"(Guest editor) The international workshop on 11beta and 17beta-hydroxysteroid dehydrogenases (special issue)","volume":"248","author":"Adamski J","year":"2006","unstructured":"Adamski J. (Guest editor) The international workshop on 11beta and 17beta-hydroxysteroid dehydrogenases (special issue). Mol Cell Endocrinol 2006;248:1-250","journal-title":"Mol Cell Endocrinol"},{"key":"e_1_3_2_47_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2009.01.012","article-title":"(Guest editor) Pre-receptor steroid metabolism as target for pharmacological treatment (special issue)","volume":"301","author":"Adamski J","year":"2009","unstructured":"Adamski J. (Guest editor) Pre-receptor steroid metabolism as target for pharmacological treatment (special issue). Mol Cell Endocrinol 2009;301:1-282","journal-title":"Mol Cell Endocrinol"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23350"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.18.3.0302"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1677\/jme.0.0250001"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(00)00155-2"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-2760(98)00066-6"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.03702.x"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1677\/jme.0.0230001"},{"key":"e_1_3_2_55_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.mce.2005.12.005","article-title":"Control of cell proliferation by steroids: the role of 17beta-HSDs","volume":"248","author":"Vihko P","year":"2006","unstructured":"Vihko P, Herrala A, Harkonen P, Control of cell proliferation by steroids: the role of 17beta-HSDs. Mol Cell Endocrinol 2006;248:141-8","journal-title":"Mol Cell Endocrinol"},{"key":"e_1_3_2_56_1","first-page":"123","article-title":"The selective estrogen enzyme modulators in breast cancer: a review","volume":"1654","author":"Pasqualini JR","year":"2004","unstructured":"Pasqualini JR. The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta 2004;1654:123-43","journal-title":"Biochim Biophys Acta"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-08-0042"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.00613.x"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0030041"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(98)00043-0"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0303-7207(00)00427-5"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.11.5.789"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867033368222"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152009788680000"},{"key":"e_1_3_2_65_1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/187221407780831957","article-title":"Hydroxysteroid dehydrogenase (17beta-HSD3, 17beta-HSD5 and 3alpha-HSD3) inhibitors: extragonadal regulation of intracellular sex steroid hormone levels","volume":"1","author":"Mohler ML","year":"2007","unstructured":"Mohler ML, Narayanan R, He Y, Hydroxysteroid dehydrogenase (17beta-HSD3, 17beta-HSD5 and 3alpha-HSD3) inhibitors: extragonadal regulation of intracellular sex steroid hormone levels. Recent Pat Endocr Metab Immune Drug Discov 2007;1:103-8","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986708783330629"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2008.01.044"},{"key":"e_1_3_2_68_1","unstructured":"Washington University. Open D ring hormone analogs. WO8706462; 1987"},{"key":"e_1_3_2_69_1","doi-asserted-by":"crossref","first-page":"7295","DOI":"10.1021\/bi00371a008","article-title":"Mechanism based inactivation of 17\/3,20alpha-hydroxysteroid dehydrogenase by an acetylenic secoestradiol","volume":"25","author":"Auchus RJ","year":"1986","unstructured":"Auchus RJ, Covey DF. Mechanism based inactivation of 17\/3,20alpha-hydroxysteroid dehydrogenase by an acetylenic secoestradiol. Biochemistry 1986;25:7295-300","journal-title":"Biochemistry"},{"key":"e_1_3_2_70_1","doi-asserted-by":"crossref","first-page":"11640","DOI":"10.1016\/S0021-9258(18)37832-3","article-title":"Solid-state NMR observation of cysteine and lysine Michael adducts of inactivated estradiol dehydrogenase","volume":"263","author":"Auchus RJ","year":"1988","unstructured":"Auchus RJ, Covey DF, Bork V, Schaefer JJ. Solid-state NMR observation of cysteine and lysine Michael adducts of inactivated estradiol dehydrogenase. Biol Chem 1988;263:11640-5","journal-title":"Biol Chem"},{"key":"e_1_3_2_71_1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0039-128X(89)90147-5","article-title":"Preparation of 14,15-secoestra-1,3,5(10)-trien-15-ynes, inhibitors of estradiol dehydrogenase","volume":"53","author":"Auchus RJ","year":"1989","unstructured":"Auchus RJ, Palmer JO, Carrell HL, Covey DF. Preparation of 14,15-secoestra-1,3,5(10)-trien-15-ynes, inhibitors of estradiol dehydrogenase. Steroids 1989;53:77-96","journal-title":"Steroids"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00171a002"},{"key":"e_1_3_2_73_1","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/S0021-9258(19)81031-1","article-title":"Inactivation of human placental 17beta-estradiol dehydrogenase and 20alpha-hydroxysteroid dehydrogenase with active site-directed 17beta-propynyl-substituted progestin analogs","volume":"257","author":"Tobia B","year":"1982","unstructured":"Tobia B, Covey DF, Strickler RC. Inactivation of human placental 17beta-estradiol dehydrogenase and 20alpha-hydroxysteroid dehydrogenase with active site-directed 17beta-propynyl-substituted progestin analogs. J Biol Chem 1982;257:2783-6","journal-title":"J Biol Chem"},{"key":"e_1_3_2_74_1","doi-asserted-by":"crossref","first-page":"11500","DOI":"10.1016\/S0021-9258(17)44255-4","article-title":"Inactivation of human placental 17beta,20alpha-hydroxysteroid dehydrogenase by 16-methylene estrone and affinity alkylator enzymatically generated from 16-methylene estradiol-17beta","volume":"258","author":"Thomas JL","year":"1983","unstructured":"Thomas JL, LaRochelle MC, Covey DF, Strickler RC. Inactivation of human placental 17beta,20alpha-hydroxysteroid dehydrogenase by 16-methylene estrone and affinity alkylator enzymatically generated from 16-methylene estradiol-17beta. J Biol Chem 1983;258:11500-4","journal-title":"J Biol Chem"},{"key":"e_1_3_2_75_1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0022-3565(25)24418-4","article-title":"Enhancement of estradiol potency by the 17beta-hydroxysteroid dehydrogenase inhibitor, 16-methylene E2 in vivo","volume":"244","author":"McDonald ZA","year":"1988","unstructured":"McDonald ZA, Slikker W Jr, Fu PP, Enhancement of estradiol potency by the 17beta-hydroxysteroid dehydrogenase inhibitor, 16-methylene E2 in vivo. J Pharm Exp Ther 1988;244:428-31","journal-title":"J Pharm Exp Ther"},{"key":"e_1_3_2_76_1","unstructured":"Endorecherche Inc. Androgen derivatives for use in the inhibition of sex steroid activity. WO9100732; 1991"},{"key":"e_1_3_2_77_1","unstructured":"Endorecherche Inc. Combination therapy for prophylaxis and\/or treatment of benign prostatic hyperplasia. WO9100731; 1991"},{"key":"e_1_3_2_78_1","unstructured":"Endorecherche Inc. Method of treatment of androgen-related diseases. WO9100733; 1991"},{"key":"e_1_3_2_79_1","first-page":"610","article-title":"Novel compounds inhibit estrogen formation and action","volume":"52","author":"Labrie C","year":"1992","unstructured":"Labrie C, Martel C, Dufour JM, Novel compounds inhibit estrogen formation and action. Cancer Res 1992;52:610-15","journal-title":"Cancer Res"},{"key":"e_1_3_2_80_1","unstructured":"Endorecherche Inc. Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use. WO9946279; 1999"},{"key":"e_1_3_2_81_1","unstructured":"Endorecherche Inc. Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use. US20040082556; 2004"},{"key":"e_1_3_2_82_1","unstructured":"Endorecherche Inc. Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use. US6541463; 2003"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2004.03.002"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2008.03.020"},{"key":"e_1_3_2_85_1","unstructured":"Snow Brand Milk Products Co. Ltd. Novel benzofuranone derivatives and process for producing the same. WO9830556; 1998"},{"key":"e_1_3_2_86_1","unstructured":"Snow Brand Milk Products Co. Ltd. Novel tetralone or benzopyranone derivatives and process for producing the same. WO9832724; 1998"},{"key":"e_1_3_2_87_1","unstructured":"Snow Brand Milk Products Co. Ltd. Remedies for hormone-dependent diseases. WO9912540; 1999"},{"key":"e_1_3_2_88_1","unstructured":"Snow Brand Milk Products Co. Ltd. New benzofuranone derivative and production thereof. JP2000038382; 2000"},{"key":"e_1_3_2_89_1","unstructured":"University College Cardiff Consultants Ltd. Benzyl tetralins formulations and uses thereof. WO0142181; 2001"},{"key":"e_1_3_2_90_1","unstructured":"Bayer Corp. 17-Beta-hydroxysteroid dehydrogenase-II inhibitors. WO0226706; 2002"},{"key":"e_1_3_2_91_1","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.tetlet.2005.01.003","article-title":"4,5-Disubstituted cis-pyrrolidinones as inhibitors of 17beta-hydroxysteroid dehydrogenase II. Part 1: synthetic approach","volume":"46","author":"Cook JH","year":"2005","unstructured":"Cook JH, Baryza J, Brennan C, 4,5-Disubstituted cis-pyrrolidinones as inhibitors of 17beta-hydroxysteroid dehydrogenase II. Part 1: synthetic approach. Tetrahedron Lett 2005;46:1525-7","journal-title":"Tetrahedron Lett"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2005.04.025"},{"key":"e_1_3_2_93_1","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1016\/j.bmcl.2006.06.041","article-title":"4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate","volume":"16","author":"Wood J","year":"2006","unstructured":"Wood J, Bagi CM, Akuche C, 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate. Bioorg Med Chem Lett 2006;16:4965-8","journal-title":"Bioorg Med Chem Lett"},{"key":"e_1_3_2_94_1","unstructured":"Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. WO03022835; 2003"},{"key":"e_1_3_2_95_1","unstructured":"Schering Corp. Piperidine and piperazineacetamines as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. WO03033487; 2003"},{"key":"e_1_3_2_96_1","unstructured":"Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US20030232837; 2003"},{"key":"e_1_3_2_97_1","unstructured":"Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US20040132736; 2004"},{"key":"e_1_3_2_98_1","unstructured":"Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US6903102; 2005"},{"key":"e_1_3_2_99_1","unstructured":"Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US696918; 2005"},{"key":"e_1_3_2_100_1","unstructured":"Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US20060014755; 2006"},{"key":"e_1_3_2_101_1","unstructured":"Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US20060069103; 2006"},{"key":"e_1_3_2_102_1","unstructured":"Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US7138396; 2006"},{"key":"e_1_3_2_103_1","unstructured":"Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. WO2004046111; 2004"},{"key":"e_1_3_2_104_1","unstructured":"Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US20040127503; 2004"},{"key":"e_1_3_2_105_1","unstructured":"Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. WO2004060488; 2004"},{"key":"e_1_3_2_106_1","unstructured":"Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US20040138226; 2004"},{"key":"e_1_3_2_107_1","unstructured":"Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US20060142338; 2006"},{"key":"e_1_3_2_108_1","unstructured":"Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US20060148816; 2006"},{"key":"e_1_3_2_109_1","unstructured":"Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US20080004248; 2008"},{"key":"e_1_3_2_110_1","unstructured":"Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US7432268; 2008"},{"key":"e_1_3_2_111_1","unstructured":"Sterix Ltd. Compound. WO2004085457; 2004"},{"key":"e_1_3_2_112_1","unstructured":"Sterix Ltd. Compound. US20060074060; 2006"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm049045r"},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm050830t"},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm050348a"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2005.10.021"},{"key":"e_1_3_2_117_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200500087"},{"key":"e_1_3_2_118_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.mce.2005.12.003","article-title":"The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer","volume":"248","author":"Purohit A","year":"2006","unstructured":"Purohit A, Tutill HJ, Day JM, The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer. Mol Cell Endocrinol 2006;248:199-203","journal-title":"Mol Cell Endocrinol"},{"key":"e_1_3_2_119_1","unstructured":"Sterix Ltd. Compound. WO2007096647; 2007"},{"key":"e_1_3_2_120_1","unstructured":"Sterix Ltd. Compound. US20090186900; 2009"},{"key":"e_1_3_2_121_1","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1016\/j.bmc.2008.02.059","article-title":"Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design","volume":"16","author":"Allan GM","year":"2008","unstructured":"Allan GM, Vicker N, Lawrence HR, Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design. Bioorg Med Chem Lett 2008;16:4438-56","journal-title":"Bioorg Med Chem Lett"},{"key":"e_1_3_2_122_1","unstructured":"Sterix Ltd. 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3) inhibitors. WO2007003934; 2007"},{"key":"e_1_3_2_123_1","unstructured":"Sterix Ltd. Compound. US20090023710; 2009"},{"key":"e_1_3_2_124_1","unstructured":"Sterix Ltd. Compound. WO2009066072; 2009"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2008.08.005"},{"key":"e_1_3_2_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2008.08.014"},{"key":"e_1_3_2_127_1","unstructured":"Vihko P Isomaa V. Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof. WO2004080271; 2004"},{"key":"e_1_3_2_128_1","unstructured":"Vihko P Isomaa V. Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof. US20060057628; 2006"},{"key":"e_1_3_2_129_1","unstructured":"Solvay Pharmaceuticals B.V. Thiophenepyrimidinones as 17-beta-hydroxysteroid dehydrogenase inhibitors. WO2004110459; 2004"},{"key":"e_1_3_2_130_1","unstructured":"Solvay Pharmaceuticals B.V. Therapeutically active thiophenepyrimidinone compounds and their use. US20050032778; 2005"},{"key":"e_1_3_2_131_1","unstructured":"Solvay Pharmaceuticals B.V. Therapeutically active thiophenepyrimidinone compounds and their use. US20080103131; 2008"},{"key":"e_1_3_2_132_1","unstructured":"Solvay Pharmaceuticals B.V. Novel compounds and their use in therapy. US20050038053; 2005"},{"key":"e_1_3_2_133_1","unstructured":"Solvay Pharmaceuticals B.V. Novel compounds and their use in therapy. WO2005032527; 2005"},{"key":"e_1_3_2_134_1","unstructured":"Solvay Pharmaceuticals B.V. Compounds and their use in therapy. US7465739; 2008"},{"key":"e_1_3_2_135_1","unstructured":"Solvay Pharmaceuticals B.V. Novel compounds and their use in therapy. US20050176742; 2005"},{"key":"e_1_3_2_136_1","unstructured":"Solvay Pharmaceuticals B.V. Compounds and their use in therapy. US7524853; 2009"},{"key":"e_1_3_2_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2005.11.044"},{"key":"e_1_3_2_138_1","unstructured":"Solvay Pharmaceuticals B.V. Novel 17beta-hydroxysteroid dehydrogenase type 1 inhibitors. WO2005047303; 2005"},{"key":"e_1_3_2_139_1","unstructured":"Solvay Pharmaceuticals B.V. Novel 17beta-hydroxysteroid dehydrogenase type 1 inhibitors. US20050192263; 2005"},{"key":"e_1_3_2_140_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0778"},{"key":"e_1_3_2_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2005.11.042"},{"key":"e_1_3_2_142_1","unstructured":"Solvay Pharmaceuticals B.V. 17beta-HSD1 and STS inhibitors. WO2006125800; 2006"},{"key":"e_1_3_2_143_1","unstructured":"Solvay Pharmaceuticals B.V. 17beta-HSD1 and STS inhibitors. US20060281710; 2006"},{"key":"e_1_3_2_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2005.11.037"},{"key":"e_1_3_2_145_1","unstructured":"Solvay Pharmaceuticals B.V. Therapeutically active triazoles and their use. WO2008034796; 2008"},{"key":"e_1_3_2_146_1","unstructured":"Solvay Pharmaceuticals B.V. Therapeutically active triazoles and their use. US20080146531; 2008"},{"key":"e_1_3_2_147_1","unstructured":"Solvay Pharmaceuticals B.V. Substituted estratrien derivatives as 17beta HSD inhibitors. WO2008065100; 2008"},{"key":"e_1_3_2_148_1","unstructured":"Solvay Pharmaceuticals B.V. Substituted estratrien derivatives as 17beta HSD inhibitors. US20080255075; 2008"},{"key":"e_1_3_2_149_1","unstructured":"Vander Jagt DL Royer RE Deck LM. 11-Beta-hydroxysteroid dehydrogenase type 1 inhibitors as anti-obesity\/ anti-diabetes compounds and 17-beta-hydroxysteroid dehydrogenase type 1 inhibitors as useful agents for the treatment of cancers especially breast cancer. US20050228038; 2005"},{"key":"e_1_3_2_150_1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0009-2797(02)00184-9","article-title":"17beta-Hydroxysteroid dehydrogenase type 1: computational design of active site inhibitors targeted to the Rossmann fold","volume":"143","author":"Brown WM","year":"2003","unstructured":"Brown WM, Metzger LE, Barlow JP, 17beta-Hydroxysteroid dehydrogenase type 1: computational design of active site inhibitors targeted to the Rossmann fold. Chem Biol Interact 2003;143-144:481-91","journal-title":"Chem Biol Interact"},{"key":"e_1_3_2_151_1","unstructured":"Bristol-Myers Squibb Co. Methods for identifying or screening for agents that modulate 17beta-HSD3. US20050191707; 2005"},{"key":"e_1_3_2_152_1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/pros.20279","article-title":"Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3)","volume":"65","author":"Spires TE","year":"2005","unstructured":"Spires TE, Fink BE, Kick EK, Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3). Prostate 2005;65:159-70","journal-title":"Prostate"},{"key":"e_1_3_2_153_1","unstructured":"Bristol-Myers Squibb Co. Anthranilic acid derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase3. US20060135619; 2006"},{"key":"e_1_3_2_154_1","unstructured":"Bristol-Myers Squibb Co. Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase3. WO2005084296; 2005"},{"key":"e_1_3_2_155_1","unstructured":"Bristol-Myers Squibb Co. Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase3. WO2005084295; 2005"},{"key":"e_1_3_2_156_1","unstructured":"Bristol-Myers Squibb Co. Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase3. US20050192310; 2005"},{"key":"e_1_3_2_157_1","unstructured":"Bristol-Myers Squibb Co. Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase3. US7417040; 2008"},{"key":"e_1_3_2_158_1","unstructured":"Schering Aktiengesellschaft. Novel 2-substituted D-homo estra-1 3 5(10)-trienes as inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. WO2006003012; 2006"},{"key":"e_1_3_2_159_1","unstructured":"Schering Aktiengesellschaft. Novel 2-substituted estra-1 3 5(10)-trien-17-ones used in the form of inhibitors of 17beta-hydroxysteroid dehydrogenase of type 1. WO2006003013; 2006"},{"key":"e_1_3_2_160_1","unstructured":"Schering Aktiengesellschaft. New 2-substituted estra-1 3 5(10)-trien-17-ones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. US20060009434; 2006"},{"key":"e_1_3_2_161_1","unstructured":"Astellas Pharma Inc. 17beta-HSD type 5 inhibitor. WO2007100066; 2007"},{"key":"e_1_3_2_162_1","unstructured":"Astellas Pharma Inc. Benzimidazole derivative. WO2009014150; 2009"},{"key":"e_1_3_2_163_1","unstructured":"Sumitomo Chemical Co. Ltd. Coumarin compound and use thereof. WO2009031706; 2009"},{"key":"e_1_3_2_164_1","unstructured":"Sumitomo Chemical Co. Ltd. Coumarin compound and use thereof. WO2009031708; 2009"},{"key":"e_1_3_2_165_1","unstructured":"Sumitomo Chemical Co. Ltd. Coumarin compound and use thereof. WO2009031709; 2009"},{"key":"e_1_3_2_166_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2009.10.111"},{"key":"e_1_3_2_167_1","unstructured":"Universitat des Saarlandes. 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases. WO2008116920; 2008"},{"key":"e_1_3_2_168_1","unstructured":"Universitat des Saarlandes. 17Beta-hydroxysteroid-dehydrogenase-typ1-inhibitoren zur behandlung hormonabhangiger erkrankungen. DE102007015169; 2006"},{"key":"e_1_3_2_169_1","unstructured":"Universitat des Saarlandes. 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases. WO2009027346; 2009"},{"key":"e_1_3_2_170_1","unstructured":"Universitat des Saarlandes. 17Beta-hydroxysteroid dehydrogenase type 1 inhibitoren zur behandlung hormonabhangiger erkrankungen. DE102007040243; 2009"},{"key":"e_1_3_2_171_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm701447v"},{"key":"e_1_3_2_172_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm800367k"},{"key":"e_1_3_2_173_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2008.09.024"},{"key":"e_1_3_2_174_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2008.04.073"},{"key":"e_1_3_2_175_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm8006917"},{"key":"e_1_3_2_176_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm901195w"},{"key":"e_1_3_2_177_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2009.02.006"},{"key":"e_1_3_2_178_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2008.09.012"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543776.2010.505604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T19:45:59Z","timestamp":1770407159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543776.2010.505604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,20]]},"references-count":176,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1517\/13543776.2010.505604"],"URL":"https:\/\/doi.org\/10.1517\/13543776.2010.505604","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,20]]}}}